VRTX · 8-K · 20260803PR000256
Guidance / Outlook
VERTEX PHARMACEUTICALS INC / MA · 2026-08-03 · Importance 80 · Surprise 68 · From source text
Vertex raised full-year 2026 total revenue guidance to $13.1 billion-$13.2 billion from $12.95 billion-$13.1 billion previously. The outlook includes continued global uptake of ALYFTREK and TRIKAFTA, at least $500 million of non-CF product revenue from CASGEVY and JOURNAVX, and a foreign-exchange benefit of approximately 150 basis points year over year, net of hedging. Vertex maintained combined GAAP R&D, acquired IPR&D and SG&A expense guidance of $6.3 billion-$6.45 billion and non-GAAP guidance of $5.65 billion-$5.75 billion, while excluding the pending Crinetics acquisition from 2026 guidance and planning an update after the expected third-quarter 2026 closing.
Key facts
- Vertex raised full year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously. source
- Embedded in the guidance are expectations for $500 million or more in revenue from non-CF products, namely CASGEVY and JOURNAVX. source
- Vertex’s guidance continues to include an immaterial cost impact from tariffs in 2026 based on currently known tariff rates and regulations. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +3.2% | Vertex raised full year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously. |
| revenue | positive | committed | — | Embedded in the guidance are expectations for $500 million or more in revenue from non-CF products, namely CASGEVY and JOURNAVX. |